Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ARWR
ARWR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ARWR News
Casgevy Therapy Revenue Shows Significant Growth
1d ago
Benzinga
Arrowhead Pharmaceuticals Q1 2026 Earnings Call Highlights
Feb 06 2026
seekingalpha
Arrowhead Pharmaceuticals Q1 Earnings Exceed Expectations
Feb 05 2026
seekingalpha
Arrowhead Pharmaceuticals Set to Announce Q1 Earnings on February 5th
Feb 04 2026
seekingalpha
Privium Fund Management Reduces Arrowhead Holdings
Feb 03 2026
Fool
Privium Fund Management Sells Arrowhead Shares
Feb 03 2026
NASDAQ.COM
Longevity Infrastructure Market Undergoes Structural Reset
Jan 29 2026
PRnewswire
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
Jan 29 2026
Newsfilter
Arrowhead Pharmaceuticals to Host Q1 2026 Financial Results Call on February 5, 2026
Jan 20 2026
Newsfilter
Sanofi Secures Approval for Two Innovative Drugs Targeting Heart Disease and High Triglycerides
Jan 15 2026
NASDAQ.COM
Anticipate a Hectic Year for Obesity Medications with New Pills Launching
Jan 12 2026
Barron's
Arrowhead CEO Anzalone Sells 85,000 Shares for $5.44 Million
Jan 11 2026
Fool
Arrowhead CEO Anzalone Sells 85,000 Shares for $5.44 Million
Jan 11 2026
NASDAQ.COM
Arrowhead Pharmaceuticals Prices $625M Convertible Notes and 3.1M Shares Offering
Jan 08 2026
Businesswire
Arrowhead Secures NMPA Approval for REDEMPLO to Treat High Triglycerides in China
Jan 07 2026
Businesswire
Arrowhead Pharmaceuticals Plans $500M Convertible Notes and $200M Stock Offering
Jan 06 2026
Businesswire
Show More News
